ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Obstetric and Pediatric Pharmacology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1634089
This article is part of the Research TopicInsights in Obstetric and Pediatric Pharmacology: 2025View all articles
A Comprehensive Clinical Evaluation of Levocetirizine in the Treatment of Chronic Urticaria in Children
Provisionally accepted
- 1Qingdao Women and Children's Hospital, Qingdao, China
- 2Ocean University of China, Qingdao, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective Levocetirizine is a second-generation antihistamine that is the first-line drug recommended by the guidelines for the treatment of chronic urticaria in children. However, the current study focused mainly on adults, and a comprehensive evaluation of children has not been reported. Therefore, comprehensive clinical evaluation of levocetirizine in the treatment of chronic urticaria in children is crucial for providing rational clinical drug use and improving the basis of relevant national policies. To conduct a comprehensive clinical evaluation of levocetirizine in the treatment of chronic urticaria in children and provide a reference for rational drug use and related policy decisions in clinical practice.Methods A comprehensive clinical evaluation index system for the use of antiallergic drugs in children was established via a literature review, expert interviews, and the Delphi method. Evidence was collected to evaluate the safety, efficiency, economy, suitability, accessibility and innovation of levocetirizine and loratadine for the treatment of chronic urticaria in children.The comprehensive clinical evaluation index system included 6 primary indicators, 12 secondary indicators, and 25 tertiary indicators. The total clinical comprehensive evaluation score of levocetirizine was 92.83, whereas that of loratadine was 72.49. The former is superior to the latter in terms of safety, effectiveness, suitability, innovation, and accessibility, whereas the latter is more cost-effective than the former.The comprehensive clinical value of levocetirizine is greater than that of loratadine in the treatment of chronic urticaria in children, which can provide evidence for the rational use of antiallergic drugs and drug catalog selection in medical institutions.
Keywords: Levocetirizine1, Xyzal 2, Loratadine3, children4, Chronic urticaria5, Clinical comprehensive evaluation6
Received: 23 May 2025; Accepted: 22 Jul 2025.
Copyright: © 2025 Liu, Zhang, Liu and Yan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Meixing Yan, Qingdao Women and Children's Hospital, Qingdao, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.